FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women - FDA Press Releases

FDA approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

from FDA Press Releases RSS Feed http://bit.ly/2ISSd3m
via IFTTT